Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

NCT04069273 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer
GastroEsophageal Cancer
Adenocarcinoma

Interventions

DRUG: Pembrolizumab Monotherapy
DRUG: Ramucirumab
DRUG: Paclitaxel

Sponsor

Harry H Yoon

Collaborators

[object Object]
[object Object]